\xe2\x80\xa2 Evaluate systems and processes used to produce products such as vaccine \xe2\x80\xa2 Ensure products meet company requirements. \xe2\x80\xa2 Run test and analyze document results \xe2\x80\xa2 Monitor compliance with safety and quality regulations \xe2\x80\xa2 Calibrating and repairing systems \xe2\x80\xa2 Designing testing protocols \xe2\x80\xa2 Purchasing and maintaining equipment \xe2\x80\xa2 To report to the superior in a timely manner \xe2\x80\xa2 To attend ad-hoc request
SGB has incorporated a new wholly-owned subsidiary, Solution Biologics Sdn. Bhd., to undertake the supply of vaccines and biologics. For the initial phase of the business, Solution Biologics Sdn. Bhd will operates a fill and finish facility dedicated to vaccines and biologics. The facility will be housed in the current manufacturing building at Technology Park Malaysia and expected to be operational by first quarter of 2021. Biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market. Since biologics are quite large in comparison to chemical-based drugs and made up of proteins, they require extra care to maintain their size, shape, form, and stability. These factors correlate to the intended effect and efficiency of the biologic drug. We are committed to developing newer and more effective vaccines and biologics through research and development programme with our partners. Our plan for the future will include paediatric and adult vaccines that are part of the National Immunisation Schedule of Malaysia and the Extended Programme of Immunisation (EPI) of various countries in the region.
Bachelor\'s or Equivalent